Complement Therapeutics (CTx) has enrolled the first patient in its study of people diagnosed with geographic atrophy (GA).
The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA, by enabling the identification of patients with complement-driven AMD for future interventional studies.
Also called late dry age-related macular degeneration (AMD), GA is a disease which causes irreversible blindness and currently has no approved treatments.
The i-GAIN (investigating Geographic Atrophy Insights) study is a one-year natural history study in patients who have a confirmed diagnosis of GA in one or both eyes. It is designed to evaluate the relationship between genetics, blood biomarkers and phenotypic changes in the eyes of people with GA.
Dr Marta Ugarte, Consultant Ophthalmologist and principal investigator of the i-GAIN study said “Today’s announcement is an important milestone in enabling researchers to gain a better understanding of this disease. We look forward to generating and analysing data from the i-GAIN study, which will provide insights into how the disease progresses.”
“A deeper understanding of the natural history of GA will provide important insights supporting the development of innovative medicines which can prevent vision loss in these patients,” said Dr Rafiq Hasan, Chief Executive Officer at Complement Therapeutics.
